Form 8-K - Current report:
SEC Accession No. 0001628280-17-000328
Filing Date
2017-01-20
Accepted
2017-01-20 17:00:34
Documents
3
Period of Report
2017-01-20
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K - BOARD APPOINTMENT a8k-boardappointment.htm 8-K 21974
2 EXHIBIT 99.1 - 8K PRESS RELEASE BOARD APPOINTMENT a8k-pressreleasexboardappo.htm EX-99.1 14092
3 cumberlanda01.gif GRAPHIC 10657
  Complete submission text file 0001628280-17-000328.txt   52003
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 17539108
SIC: 2834 Pharmaceutical Preparations